Preleukemia and Leukemia-Initiating Cell Activity in inv(16) Acute Myeloid Leukemia

Frontiers in Oncology
John A Pulikkan, Lucio H Castilla

Abstract

Acute myeloid leukemia (AML) is a collection of hematologic malignancies with specific driver mutations that direct the pathology of the disease. The understanding of the origin and function of these mutations at early stages of transformation is critical to understand the etiology of the disease and for the design of effective therapies. The chromosome inversion inv(16) is thought to arise as a founding mutation in a hematopoietic stem cell (HSC) to produce preleukemic HSCs (preL-HSCs) with myeloid bias and differentiation block, and predisposed to AML. Studies in mice and human AML cells have established that inv(16) AML follows a clonal evolution model, in which preL-HSCs expressing the fusion protein CBFβ-SMMHC persist asymptomatic in the bone marrow. The emerging leukemia-initiating cells (LICs) are composed by the inv(16) and a heterogeneous set of mutations. In this review, we will discuss the current understanding of inv(16) preleukemia development, and the function of CBFβ-SMMHC related to preleukemia progression and LIC activity. We also discuss important open mechanistic questions in the etiology of inv(16) AML.

References

Feb 21, 1997·Journal of Molecular Biology·R L SohnL A Leinwand
Jul 15, 1999·Nature Structural Biology·X HuangJ H Bushweller
Nov 7, 1999·Lancet·J L WiemelsM F Greaves
Jun 8, 2001·The Journal of Biological Chemistry·M IkebeM Higashihara
Aug 13, 2002·Nature Structural Biology·Stephen M LukasikJohn H Bushweller
Jan 2, 2003·Molecular and Cellular Biology·Kristie L DurstScott W Hiebert
Mar 27, 2004·Proceedings of the National Academy of Sciences of the United States of America·L H CastillaP P Liu
Apr 16, 2004·The New England Journal of Medicine·Peter J M ValkRuud Delwel
Jan 12, 2005·Cancer Genetics and Cytogenetics·Hong ChangD Robert Sutherland
Apr 7, 2006·Leukemia·N BoisselUNKNOWN Leucémies Aiguës Myéloblastiques de l'Enfant (LAME) Cooperative Groups
Jul 25, 2007·The Journal of Experimental Medicine·Takeshi EgawaDan R Littman
Nov 7, 2008·Nature·Timothy J LeyRichard K Wilson
Aug 7, 2009·The New England Journal of Medicine·Elaine R MardisTimothy J Ley
Nov 12, 2010·The New England Journal of Medicine·Timothy J LeyRichard K Wilson
Mar 1, 2011·The Journal of Molecular Diagnostics : JMD·Jianbo SongMarilyn M Li
Jun 6, 2012·The Journal of Experimental Medicine·Wooseok SeoIchiro Taniuchi
Nov 5, 2013·Cancer Cell·Hong ZhangDaniel G Tenen

❮ Previous
Next ❯

Methods Mentioned

BETA
MDS

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.